| Document |
Document Title |
|
WO/2021/069569A1 |
The present invention relates to novel heteroaryl-triazole compounds of the general formula (I), in which the structural elements X, Y, R1, R2, R3, R4 and R5 have the meaning given in the description, to formulations and compositions com...
|
|
WO/2021/069595A1 |
The present invention relates to compound having the following Formula (I) a semiconducting layer comprising this compound, an organic electronic device comprising said organic semiconducting layer, as well as to a device comprising the ...
|
|
WO/2021/071802A1 |
A compound of Formula (I), or a pharmaceutically-acceptable salt thereof, is described, wherein the substituents are as defined herein. Pharmaceutical compositions comprising the same and method of using the same are also described.
|
|
WO/2021/071983A1 |
Described herein are agents that modify splicing of pre-mRNA and methods of making and using the same.
|
|
WO/2021/071832A1 |
A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is described, where the substituents are as defined herein. Pharmaceutical compositions including the same and method of using the same are also described.
|
|
WO/2021/069339A1 |
The present invention relates to homopiperazinyl and homopiperidinyl quinazolin- 4(3H)-one derivatives having dual pharmacological activity towards both the α2δ subunit of the voltage-gated calcium channel and the sigma-1 (σ1) recepto...
|
|
WO/2021/069567A1 |
The present invention relates to novel heteroaryl-triazole compounds of the general formula (I), in which the structural elements X, Y, R1, R2, R3a, R3b, R4 and R5 have the meaning given in the description, to formulations and compositio...
|
|
WO/2021/070090A1 |
Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formul...
|
|
WO/2021/071837A1 |
This disclosure is directed, at least in part, to GPR119 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR119 agonists are gut-restricted compounds. In some embodiment...
|
|
WO/2021/069575A1 |
The present invention relates to novel heteroaryl-substituted pyrazine derivatives of the general formula (I), in which the structural elements R1, R2, R3, R4, R5 and R6 have the meaning given in the description, to formulations and comp...
|
|
WO/2021/068179A1 |
The present invention provides novel heteroaryl-substituted pyrazine derivatives of the general formula (I), in which the structural elements R 1, R 2, R 3, R 4, R 5 and R 6 have the meaning given in the description, formulations and com...
|
|
WO/2021/068820A1 |
Disclosed in the present invention are an alkene-containing carboxylate compound and use of an agriculturally acceptable salt thereof as a herbicide. Said compound is as represented by general formula (I). The definition of the substitue...
|
|
WO/2021/071984A1 |
Described herein are agents that modify splicing of pre-mRNA and methods of making and using the same.
|
|
WO/2021/069705A1 |
Disclosed herein is a compound or pharmaceutically acceptable salts or stereoisomers thereof of of formula I wherein X1 is linear or branched C1-6 alkyl, C3-6 cycloalkyl, -C1-6 alkyl C3-6 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl,...
|
|
WO/2021/068816A1 |
Disclosed are an alkene-containing amide compound and the use of an agriculturally acceptable salt thereof as a herbicide. The compound is as represented by general formula (I): the substituents in general formula I are defined in the de...
|
|
WO/2021/071981A1 |
Described herein are agents that modify splicing of pre-mRNA and methods of making and using the same.
|
|
WO/2021/071803A1 |
A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is described, where the substituents are as defined herein. Pharmaceutical compositions including the same and method of using the same are also described.
|
|
WO/2021/070054A1 |
Compounds and pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth.
|
|
WO/2021/070132A1 |
Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Such compounds are represented by Formula I as follows: Formula I wherein R1, R2, R3,...
|
|
WO/2021/068898A1 |
The present invention pertains to the field of medicinal chemistry, and relates to a novel KRAS G12C protein inhibitor, a preparation method therefor, and a use thereof. Specifically, a compound with a structure of formula (I) is provide...
|
|
WO/2021/068953A1 |
The present invention belongs to the field of medicinal chemistry and relates to a class of substituted tricyclic compounds as PRMT5 inhibitors and the use thereof. Specifically, the present invention provides a compound represented by f...
|
|
WO/2021/066088A1 |
Provided is a compound represented by the following formula (1) and a pharmacologically acceptable salt, which have a regulatory activity for a histamine H4 receptor and are useful for the treatment and/or prevention of diseases or condi...
|
|
WO/2021/064186A1 |
The present invention concerns novel pyridin-2(1H)one derivatives, their process of preparation and their use in therapeutics, in particular as agents for treating and/or preventing pain.
|
|
WO/2021/067805A1 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...
|
|
WO/2021/067772A1 |
Formulations of Compound 1 or a pharmaceutically acceptable salt thereof are described. Also disclosed are capsules having a dry blended powder comprising Compound 1 or a pharmaceutically acceptable salt thereof. The Compound 1 or a phar...
|
|
WO/2021/064677A1 |
Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: Formula I.
|
|
WO/2021/065980A1 |
Provided is a BET degrader. A BET degrader including a compound represented by formula (I) or a pharmaceutically acceptable salt thereof is used. (In the formula, L1 and L2 are the same or different and represent a low molecular ligand f...
|
|
WO/2021/066578A1 |
The present invention relates to a compound derivative bearing a 6-7 bicyclic ring and a use thereof. The compound according to the present invention acts as a protein arginine methyltransferases 5 (PRMT5) inhibitor and thus can be advan...
|
|
WO/2021/064590A1 |
Described herein are compounds of Formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are defined herein, their use as diacylglycerol acyltransferase 2 (DGAT2) inhibitors, pharmaceutical compositions containing such inhibitors and...
|
|
WO/2021/066573A1 |
The present invention pertains to: a novel compound; and a use thereof in treating autoimmune diseases. A pharmaceutical composition for treating or preventing autoimmune diseases containing the novel compound of the present invention ca...
|
|
WO/2021/063856A1 |
The present invention provides novel compounds having the general formula (I) wherein R1 to R6 are as described herein, compositions including the compounds and methods of using the compounds.
|
|
WO/2021/067215A1 |
The present disclosure provides compounds represented by Formula (la): and the pharmaceutically acceptable salts thereof, wherein R1a, R1b, R1c, R2, R3, L, M and G are as defined as set forth in the specification. The present disclosure ...
|
|
WO/2021/063821A1 |
The present invention covers pyrimidinedione derivatives of general formula (I) : (I), in which R1, R2, R4, R5 and X are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, ...
|
|
WO/2021/064175A1 |
The present invention relates to a composition for use in preventing migration of cancer cells in a subject known or suspected to suffer from cancer, the composition comprising at least one metal complex having the structure (I), formula...
|
|
WO/2021/064142A1 |
The present invention relates to a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof : formula (I) and to pharmac...
|
|
WO/2021/067521A1 |
The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical composit...
|
|
WO/2021/066559A1 |
N-(1H-imidazol-2-yl)benzamide compound of formula (I), or a pharmaceutically acceptable salt, a prodrug, a solvate, or a stereoisomer thereof which is a novel compound exhibiting excellent inhibitory activity against IRAK-4, can be used ...
|
|
WO/2021/065492A1 |
Provided is an organic EL element which has high efficiency and high driving stability, while having low drive voltage. This organic EL element is characterized by having one or more light emitting layers between a positive electrode and...
|
|
WO/2021/067657A1 |
Disclosed are compounds of Formula (I) or salts thereof, wherein R1, R2, R3, R4, and R5 are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, 8, or 9, and pharmace...
|
|
WO/2021/063207A1 |
Provided are a compound as shown in formula (I), which formula is as follows, and racemates, stereoisomers, tautomers, isotopic markers, solvates, polymorphs and oxynitrides of the compound, or a pharmaceutically acceptable salt thereof,...
|
|
WO/2021/067266A1 |
Disclosed herein are pyrrolidinyl-based compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.
|
|
WO/2021/067801A1 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or prodrug, and/or tautomer, and/or drug combination of the compound) that inhibit (e.g., antagoniz...
|
|
WO/2021/067859A1 |
Provided herein is a compound of Formula (I), or pharmaceutically acceptable salt thereof, wherein R1, Y, X, and n are defined herein. Also provided herein are compositions comprising a compound of Formula (I) or pharmaceutically accepta...
|
|
WO/2021/067374A1 |
The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR3 enzyme and are useful in the treatment of F GFR3-associated diseases such as cancer.
|
|
WO/2021/067654A1 |
Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
|
|
WO/2021/056811A1 |
Disclosed are an imine salt derivative and a preparation method therefor, and a preparation method for nicotine. The preparation method for nicotine comprises the following steps: adding an imine salt derivative having a general formula ...
|
|
WO/2021/058754A1 |
The invention provides a composition of matter which: • (i) consists of at least 90 % by weight of an atropisomer (2A) and 0-10 % by weight of an atropisomer of formula (2B); or • (ii) consists of at least 90 % by weight of an atropi...
|
|
WO/2021/061644A1 |
The present disclosure relates to novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions. In some embodiments, the compounds disclos...
|
|
WO/2021/061053A1 |
There are provided new heterobifunctional agents designed to mediated formation of protein-protein dimers and promote ubiqutination of a protein of the dimer. Also provided are methods of synthesizing the agents, pharmaceutical formulati...
|
|
WO/2021/057890A1 |
A class of compounds that have a pyrazine structure, specifically disclosed is a compound represented by formula (VII), isomers or pharmaceutically acceptable salts thereof, and an application thereof in the preparation of CRAC inhibitors.
|
